- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07449702
En åpen merknad-forlengelsesstudie av ORKA-001 hos deltakere med plakkpsoriasis
En åpen merkeviddeforlengelsesstudie for å evaluere langsiktig sikkerhet, tolerabilitet og effekt av ORKA-001 hos deltakere med moderat til alvorlig plakkpsoriasis
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
Studieoversikt
Detaljert beskrivelse
This open-label extension study evaluates the long-term safety and efficacy of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label treatment period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last study visit.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Oruka Clinical Trials Information
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
Studiesteder
-
-
Alberta
-
Edmonton, Alberta, Canada, T5J 3S9
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Edmonton, Alberta, Canada, T6G 1C3
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3R 6A7
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Surrey, British Columbia, Canada, V3V 0C6
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
New Brunswick
-
Fredericton, New Brunswick, Canada, E3B IG9
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Ontario
-
Ajax, Ontario, Canada, L1S7K8
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
London, Ontario, Canada, N6H 5L5
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Markham, Ontario, Canada, L3P 1X3
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Peterborough, Ontario, Canada, K9J 5K2
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Toronto, Ontario, Canada, M4W 2N4
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Waterloo, Ontario, Canada, N2J 1C4
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Quebec
-
Montreal, Quebec, Canada, H2X2V1
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Québec, Quebec, Canada, G1V4X7
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85032
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Arkansas
-
North Little Rock, Arkansas, Forente stater, 72117
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
California
-
Fountain Valley, California, Forente stater, 92708
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Los Angeles, California, Forente stater, 90045
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Los Angeles, California, Forente stater, 90095
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
San Diego, California, Forente stater, 92123
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Santa Ana, California, Forente stater, 92701
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Santa Monica, California, Forente stater, 90403
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Connecticut
-
Cromwell, Connecticut, Forente stater, 06416
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Florida
-
Miami, Florida, Forente stater, 33126
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Illinois
-
Rolling Meadows, Illinois, Forente stater, 60008
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Indiana
-
Plainfield, Indiana, Forente stater, 46168
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Kentucky
-
Bowling Green, Kentucky, Forente stater, 42104
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- E-post: clinicaltrials@orukatx.com
-
-
Maryland
-
Rockville, Maryland, Forente stater, 20850
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Massachusetts
-
Boston, Massachusetts, Forente stater, 02111
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Michigan
-
Detroit, Michigan, Forente stater, 48202
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
New York
-
New York, New York, Forente stater, 10023
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
New York, New York, Forente stater, 10029
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Ohio
-
Cleveland, Ohio, Forente stater, 44106
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Mason, Ohio, Forente stater, 45040
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Oregon
-
Portland, Oregon, Forente stater, 97201
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Portland, Oregon, Forente stater, 97210
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Texas
-
Frisco, Texas, Forente stater, 75033
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Houston, Texas, Forente stater, 77004
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
Webster, Texas, Forente stater, 77598
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Therapeutics Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Virginia
-
Norfolk, Virginia, Forente stater, 23502
- Rekruttering
- Oruka Therapeutics Investigative Site
-
Ta kontakt med:
- Oruka Investigative Site
- Telefonnummer: 781-560-0299
- E-post: clinicaltrials@orukatx.com
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Signed informed consent by participants from previous trial choosing to transition into the OLE.
- Participants who have successfully completed the preceding trial.
- For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
- For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception
Exclusion Criteria:
- Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
- Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
- Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
- Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
- Participant is pregnant or breastfeeding.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: ORKA-001 Once Yearly (High Dose)
Participants will receive ORKA-001 once a year per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Eksperimentell: ORKA-001 Once Yearly (Low Dose)
Participants will receive ORKA-001 once a year per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Eksperimentell: ORKA-001 Twice Yearly
Participants will receive ORKA-001 every 6 months per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
Ingen inngripen: No Drug
Participants will receive no drug until protocol defined PASI response criterion is met. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
Tidsramme: Day 1 through Week 144
|
Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms. |
Day 1 through Week 144
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Participants Maintaining PASI100 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining PASI90 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0/1 in the Subset of Participants Meeting the Criterion at Baseline of OLE
Tidsramme: Time Frame: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Time Frame: Day 1 through Week 96
|
|
Proportion of Participants with an Improvement of their OLE Baseline PASI Score in the Subset of Participants who did not Achieve PASI75 at OLE Baseline
Tidsramme: Day 1 through Week 96
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Time-to-loss of PASI100 in the Subset of Participants who achieved PASI100 at Baseline of OLE
Tidsramme: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Time-to-loss of PASI90 in the Subset of Participants who achieved PASI90 at Baseline of the OLE
Tidsramme: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
PASI Score Over Time
Tidsramme: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
IGA Score Over Time
Tidsramme: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Day 1 through Week 96
|
Samarbeidspartnere og etterforskere
Sponsor
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- ORKA-001-113
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .